Get the Stockscreener App
288.24
0.79%
2.25
Abbvie Inc stock is traded at $288.24, with a volume of 1.72M.
It is up +0.79% in the last 24 hours and up +9.48% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$285.99
Open:
$291
24h Volume:
1.72M
Relative Volume:
0.35
Market Cap:
$509.35B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
142.17
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+1.07%
1M Performance:
+9.48%
6M Performance:
+41.37%
1Y Performance:
+28.03%
1-Day Range:
$288.04
$292.67
1-Week Range:
$281.23
$289.59
52-Week Range:
$190.75
$292.67
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
288.24 | 509.35B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,368.14 | 1.22T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
274.55 | 660.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
147.73 | 364.48B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.22 | 302.59B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie stock hits all-time high at 291.65 USD - Investing.com
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research
Arcutis Appoints Rob Scott, MD to Board of Directors - GlobeNewswire Inc.
AbbVie files etentamig application: what it means for AbbVie stock - ad-hoc-news.de
AbbVie: Still Strong Growth, But Patent Cliff Getting Closer (NYSE:ABBV) - Seeking Alpha
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research
AbbVie announces Q3 2026 earnings call while stock holds steady - Traders Union
I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend - CNBC
AbbVie hits record highs with strong 2026 outlo... - Pluang
AbbVie Files FDA BLA for Etentamig in Multiple Myeloma, Ticker A - GuruFocus
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy) (NYSE:ABBV) - Seeking Alpha
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView
Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)? - Zacks Investment Research
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.
AbbVie (ABBV) Q3 2026 Preview: EPS Est. $3.78, Reports October 30 - AlphaStreet
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30 - 24/7 Wall St.
Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? - The Motley Fool
AbbVie wins Crohn's approval: what it means for AbbVie stock - ad-hoc-news.de
Should You Invest in the iShares U.S. Healthcare ETF (IYH)? - Zacks Investment Research
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy - The Motley Fool
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF - The Motley Fool
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research
Abbvie, Vertex lead $32B September biopharma M&A surge - BioWorld News
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
AbbVie stock: Cantor lifts target for AbbVie stock from USD 285 to USD 290 - ad-hoc-news.de
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
AbbVie Inc. (ABBV80.BK) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts - Yahoo Finance
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - The Globe and Mail
AbbVie stock: At 1.84 percent below its 52-week high, AbbVie stock trades at EUR 255.05 - ad-hoc-news.de
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying? - Yahoo Finance
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
AbbVie ABBV-466 Achieves 40.5% Crohn's Remission - grafa.com
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - TradingView
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - TradingView
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbvie Inc Stock (ABBV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Aug 14 '26 |
Sale |
250.00 |
32,710 |
8,177,500 |
74,430 |
| NICHOLAS DONOGHOE | Officer |
Aug 14 '26 |
Proposed Sale |
250.00 |
32,710 |
8,177,500 |
0 |
| ROBERT J ALPERN | Director |
May 26 '26 |
Proposed Sale |
214.00 |
13,000 |
2,781,991 |
0 |
| Purdue David Ryan | SVP, Controller |
Mar 04 '26 |
Sale |
233.56 |
5,230 |
1,221,519 |
2,654 |
| David R. Purdue | Officer |
Mar 04 '26 |
Proposed Sale |
233.56 |
5,230 |
1,221,519 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Mar 02 '26 |
Sale |
234.39 |
18,668 |
4,375,549 |
4,619 |
| PERRY C SIATIS | Officer |
Mar 02 '26 |
Proposed Sale |
234.39 |
18,668 |
4,375,585 |
0 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Option Exercise |
172.62 |
22,381 |
3,863,458 |
60,518 |
| Siatis Perry C | EVP, GC AND SECRETARY |
Feb 25 '26 |
Sale |
230.00 |
22,381 |
5,147,630 |
38,137 |
| PERRY C SIATIS | Officer |
Feb 25 '26 |
Proposed Sale |
230.00 |
22,381 |
5,147,630 |
0 |
4.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):